SECTION 1 : PROGRESS
THE MICHAEL J . FOX FOUNDATION 2022 IN REVIEW
6
Early Disease : A Critical Window for Driving Treatments
The earliest days and years with Parkinson ’ s represent a critical but fleeting opportunity for patients to take part in research toward strategies to halt the disease and its symptoms from progressing . Currently , there are some 71 diverse such treatments in testing . The Michael J . Fox Foundation ( MJFF ) also continues to drive the search for objective measures of disease ( biomarkers — like , for example , hypertension in heart disease ). In any disease , biomarkers flag risk , allow for early diagnosis , and aid tailored intervention . In Parkinson ’ s , they would bring diseasemodifying therapies closer to reality . Today , validated and reliable biomarkers remain a critical missing link in Parkinson ’ s disease ( PD ) research .